WEBULL

DSM-Firmenich (ENXTAM:DSFIR) Buyback Puts Its Valuation Narrative Back In Focus

Simply Wall St · 1d ago

DSM-Firmenich (ENXTAM:DSFIR) has launched a share repurchase program that targets €500 million of ordinary shares to reduce issued capital, alongside €40 million earmarked for share-based compensation commitments.

See our latest analysis for DSM-Firmenich.

At a share price of €83.38, DSM-Firmenich has a 90 day share price return of 31.18% and a year to date share price return of 21.12%. Its 1 year total shareholder return of 2.13% and 3 year total shareholder return that declined 1.41% suggest recent momentum has picked up after a softer longer term experience.

If this buyback has you thinking about where else capital is moving, it could be a good moment to hunt for emerging opportunities through the 106 top founder-led companies

For DSM-Firmenich, a 90 day surge alongside a sizeable buyback raises a simple question: Are you mainly seeing renewed confidence in the business, or a sentiment swing that the current valuation needs to test next?

Most Popular Narrative: 5.1% Overvalued

With DSM-Firmenich closing at €83.38 against a most-followed fair value estimate of €79.37, the narrative points to a modest premium and puts the merger story and portfolio shift under the spotlight.

The rollout of innovative, health-focused ingredients (e.g., reduced sugar, salt, and enriched with healthy components) and strong demand for preventative health products positions DSM-Firmenich to benefit from growing consumer health and wellness trends, supporting sustained organic revenue growth in key segments like Taste, Texture & Health and Health, Nutrition & Care.

Investment in fermentation and bio-based solutions (e.g., Amberever, algal lipids, HMOs) alongside the exit from lower-margin, less sustainable businesses, is expected to lead to higher product differentiation, pricing power, and margin expansion aligned with rising preferences for sustainable alternatives.

Read the complete narrative.

Want to understand why this premium might still look justified on paper? The narrative leans on steadier revenue compounding, fatter margins, and a future earnings multiple that assumes DSM-Firmenich earns a slot alongside higher quality compounders.

Result: Fair Value of €79.37 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, DSM-Firmenich still faces two key pressure points that could challenge this premium: softer demand from larger global customers and ongoing foreign exchange hits to reported earnings.

Find out about the key risks to this DSM-Firmenich narrative.

Another View On DSM-Firmenich's Value

Analysts currently frame DSM-Firmenich as about 5.1% above their €79.37 fair value estimate. Our DCF model points in a different direction. It suggests a future cash flow value of €131.58 per share, which is 36.6% above the current €83.38 price.

This gap shows how sensitive DSM-Firmenich's value is to long term cash flow assumptions. If the market leans closer to the DCF view rather than the analyst target, the current premium to consensus might look different to you.

Look into how the SWS DCF model arrives at its fair value.

DSFIR Discounted Cash Flow as at Jul 2026
DSFIR Discounted Cash Flow as at Jul 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out DSM-Firmenich for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 250 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of optimism and caution around DSM-Firmenich feels finely balanced, it is worth checking the data yourself and forming a clear view quickly. To see the full breakdown of both potential upsides and areas of concern, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond DSM-Firmenich?

If DSM-Firmenich has sharpened your focus, now may be a good moment to broaden your watchlist using targeted stock ideas that match your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.